Home » Stocks » Dare Bioscience

Dare Bioscience, Inc. (DARE)

Stock Price: $1.00 USD -0.01 (-0.99%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $1.01 +0.01 (1.00%) Oct 22, 7:23 PM

Stock Price Chart

Key Info

Market Cap 31.55M
Revenue (ttm) n/a
Net Income (ttm) -18.64M
Shares Out 31.55M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $1.00
Previous Close $1.01
Change ($) -0.01
Change (%) -0.99%
Day's Open 1.00
Day's Range 1.00 - 1.02
Day's Volume 258,453
52-Week Range 0.69 - 2.22

More Stats

Market Cap 31.55M
Enterprise Value 27.17M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.55M
Float 28.42M
EPS (basic) -0.86
EPS (diluted) -0.87
FCF / Share -0.66
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 115,177
Short Ratio 0.24
Short % of Float 0.41%
Beta 1.43
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 105.43
Revenue n/a
Operating Income -18.66M
Net Income -18.64M
Free Cash Flow -17.67M
Net Cash 4.39M
Net Cash / Share 0.14
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -147.33%
ROE -690.95%
ROIC 2,223.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.10*
(410.00% upside)
Low
3.00
Current: $1.00
High
7.50
Target: 5.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue-----0.080.010.63
Revenue Growth-----1233.33%-99.04%-
Gross Profit-----0.080.010.63
Operating Income-14.34-16.88-11.18-0.63-37.17-20.28-15.86-21.58
Net Income-14.26-16.74-11.50-0.67-39.59-23.34-17.14-22.10
Shares Outstanding15.5810.733.230.842.541.450.070.06
Earnings Per Share-0.97-1.57-3.56-0.81-15.60-16.00-250.50-363.90
Operating Cash Flow-13.32-10.27-2.54-0.37-31.92-19.06-16.61-21.01
Capital Expenditures--0.01---0.25-0.19-0.01-0.18
Free Cash Flow-13.32-10.28-2.54-0.37-32.17-19.25-16.62-21.19
Cash & Equivalents4.786.817.560.0475.9151.175.4916.71
Total Debt0.800.01-0.7020.323.1215.089.13
Net Cash / Debt3.986.807.56-0.6555.5848.05-9.597.58
Assets7.447.8314.260.0478.2353.396.8317.66
Liabilities7.001.100.970.7629.488.0710197.70
Book Value0.446.7313.29-0.7148.7445.33-94.30-80.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Dare Bioscience, Inc.
Country United States
Employees 15
CEO Sabrina Martucci Johnson

Stock Information

Ticker Symbol DARE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DARE

Description

Daré Bioscience, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy. The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company is headquartered in San Diego, California.